Although some sexual side effects of GLP-1s may be related to the medications themselves, others come from weight loss or changes to body image
Eli Lilly said it will continue to monitor results from the trial
Consultado el 27 de enero de 2026: Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease, Lily
Use of Zepbound has been associated with acute kidney injury, which can result from dehydration due to gastrointestinal adverse reactions to Zepbound
Appetite suppression: By binding to GLP-1 receptors in your brain, both medications help you feel fuller and less hungry
PlexusDx recommends patients schedule their injections with a specific time as well as date, which reduces the chance of confusion